Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 12
Summary
- Conditions
- Chronic Lymphocytic Leukemia
- Richter Syndrome
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02535286
- Collaborators
- Memorial Sloan Kettering Cancer Center
- Investigators
- Study Chair: Anthony R. Mato, MD Memorial Sloan Kettering Cancer Center